Clinical trials: Metastatic Pleural Effusions
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Metastatic Breast Cancer
IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer
Change of IL-6 and IL-8 level in blood and pleural effusion before and after chemotherapy correlate with the prognosis of the disease
- Trial name
- NCT01543126
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fudan University
Pleural Effusion, Malignant
Pleural Carcinomatosis Tissue Banking
Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. About 28% of patients with primary malignancy will develop pleural metastasis.
- Trial name
- TICP (NCT04844827)
- Testing
- Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily
- Where
- France
- Volunteers
- 143 people
- Sponsor
- Hospices Civils de Lyon
Metastatic Cancer
Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions
RATIONALE: Some drugs such as bleomycin or doxycycline, or other compounds like talc, may help to control fluid in the chest caused by cancer.
- Trial name
- NCT00002872
- Testing
- bleomycin sulfate, doxycycline, talc
- Volunteers
- 480 people
- Sponsor
- Eastern Cooperative Oncology Group
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington